argenx SE (STU:1AE)
€ 553.6 6 (1.1%) Market Cap: 33.43 Bil Enterprise Value: 30.56 Bil PE Ratio: 0 PB Ratio: 8.44 GF Score: 82/100

argenx SE at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 09:50AM GMT
Release Date Price: €202.8 (+2.79%)
Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Good morning, everyone. Thank you so much for joining us today. Today, with us is Tim, CEO of argenx. Tim cofounded argenx and has served as CEO since April 28 -- 2008, and he has more than 20 years of general management experience across the life sciences and consumer good sectors. Good morning, Tim, how are you?

Timothy Van Hauwermeiren
argenx SE - CEO & Executive Director

I'm fine. Thank you. Thank you for having us today.

Questions & Answers

Tazeen Ahmad
BofA Merrill Lynch, Research Division - VP

Yes. So maybe before we get started and dive deeper into the company's pipeline, can you give us an overview of your company and maybe highlight some of the recent developments?

Timothy Van Hauwermeiren
argenx SE - CEO & Executive Director

Sure, very happy to do so. So we are a late-stage biotech company, getting ready for our first commercial launch next year, where we're trying to reach patients

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot